Vascular Response to Everolimus- and Biolimus-Eluting Coronary Stents Versus Everolimus-Eluting Bioresorbable Scaffolds – an Optical Coherence Tomography Substudy of the EVERBIO II Trial. Swiss Med Wkly 2016, 146 (0102), w14274. https://doi.org/10.4414/smw.2016.14274.